Lopinavir/Ritonavir as an Immunomodulator to Enhance Vaccine Responsiveness.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2014
At a glance
- Drugs Lopinavir (Primary) ; Ritonavir (Primary) ; Rabies vaccine
- Indications Hodgkin's disease; Rabies
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 22 May 2012 Planned End Date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 11 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.